Innovent Biologics, Inc. (HKG:1801)
82.05
-7.05 (-7.91%)
Oct 22, 2026, 2:05 PM HKT
Innovent Biologics Employees
Innovent Biologics had 8,754 employees as of June 30, 2026. The number of employees increased by 1,252 or 16.69% since the number was reported on December 31, 2025. That makes Innovent Biologics the 3,730th largest employer in the world and 313th in Hong Kong.
Employees
8,754
Change
1,252
Growth
16.69%
Revenue / Employee
2.07M HKD
Profits / Employee
162.53K HKD
Market Cap
142.84B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 8,754 | 1,252 | 16.69% |
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| BeOne Medicines AG | 12,000 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
Innovent Biologics News
- 13 days ago - Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease - Nasdaq
- 13 days ago - Innovent's SYCUME Delivers Phase 3 Win In Inactive Thyroid Eye Disease - Nasdaq
- 13 days ago - Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease - PRNewsWire
- 22 days ago - Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma - Nasdaq
- 23 days ago - Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL - Nasdaq
- 23 days ago - Innovent Biologics announces China NMPA approves Jaypirca for new indication - TheFly
- 23 days ago - Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy - PRNewsWire
- 24 days ago - Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down - Nasdaq